Bio valve freedom from reop in "younger" patients
Bio valve freedom from reop in "younger" patients
Ah, now I understand!
I just looked at the two large studies published in the last year cited by St. Jude.
1. 20 years experience in 1712 patients
http://www.sjmprofessional.com/Reso...ts-with-the-Biocor-Porcine-Bioprosthesis.aspx
An abstract of the study with some critical numbers is available here, and you can buy a pdf of the full study:
http://jtcs.ctsnetjournals.org/cgi/content/abstract/137/1/76
2. 20 years experience in 455 patients
http://www.sjmprofessional.com/Reso...cor-Bioprosthesis-in-the-Aortic-Position.aspx
The full text of the latter article is available here:
http://ats.ctsnetjournals.org/cgi/reprint/86/4/1204
I now understand that Dr. Miller, my surgeon, is right in saying the new 3rd generation valves are not significantly better than earlier generations in terms of freedom from reoperation. It isn't that he doesn't believe the data. If you look at the subset of patients less than 65 years old, the reop rates at 15 years in these two studies are about 50%. These are no 20 year+ valves in "younger" patients, like me. Yes, in patients older than 65 the freedom from reop might well be over 90% at 15 years and close to 90 at 20 years, but the data is sparse. In the scheme of things, these are very small trials.
That still doesn't mean I might not choose to get one of these valves. I just now understand that Dr. Miller is not particularly biased in his view. He just was referring to my age subgroup. There are many reviews with the earlier generation bio valves that show similar reop rates in younger patients.
I see in reading some other posts that you guys seem to be aware of this, but I see a lot of indiscriminate mention of new "20 year" bio valves too. I didn't pick up the age dependence until today. And even that can be subject to some serious question, as the average follow-up in the studies was only 6 and 8 years, so there is a lot of statistical extrapolation (life table analysis) going on here and the number of patients out over 10 years is quite small due to many deaths. For the vast majority of patients who entered these trials the re-op interval was irrelevant as they died relatively early before they could reach a projected 15 or 20 year re-op. Maybe that's something for all of us to consider. I did note that there was a high rate of coronary disease in the patients in these trials, so that may be an important factor. Dr. Miller, when he strongly recomended the mechancial valve, noted my coronaries are clean and I am going to live a long time. It's commonly held that 90% of the medical literature is seriously flawed in terms of study design or results analysis and interpretation, and I don't think these studies are in the exempt group.